Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Landy J and Hart AL | Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336680 |
Hirai F et al. | Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336690 |
Schmidt KJ et al. | Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336691 |
Srinivas NR | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589592 |
BenÃtez C et al. | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589580 |
Yamamoto T et al. | Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. | 2016 | Aliment. Pharmacol. Ther. | pmid:26762838 |
Travis S | Review article: saving the colon in severe colitis - the case for medical therapy. | 2006 | Aliment. Pharmacol. Ther. | pmid:16961749 |
Schmidt KJ et al. | Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. | 2013 | Aliment. Pharmacol. Ther. | pmid:23121200 |
Yamamoto S et al. | Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. | 2008 | Aliment. Pharmacol. Ther. | pmid:18549460 |
O'Leary JG | Editorial: tacrolimus-how low can you go? | 2017 | Aliment. Pharmacol. Ther. | pmid:28589579 |
Firpi RJ et al. | Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113371 |
Herrlinger KR et al. | Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20175769 |
Solari S et al. | Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. | 2017 | Aliment. Pharmacol. Ther. | pmid:28261844 |
Schwrer H et al. | Pantoprazole and cyclosporine or tacrolimus. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284790 |
Nakase H et al. | Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy. | 2011 | Aliment. Pharmacol. Ther. | pmid:21434949 |
Nakase H et al. | Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? | 2011 | Aliment. Pharmacol. Ther. | pmid:21198700 |
Hoshino H et al. | Effects of FK506 on an experimental model of colitis in rats. | 1995 | Aliment. Pharmacol. Ther. | pmid:7544633 |
Mehta SJ et al. | Review article: strategies for the management of chronic unremitting ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23718288 |
Yamamoto T et al. | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040167 |
Taylor KM and Sparrow MP | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040166 |